AstraZeneca shares rebound as Reuters report rules out Bristol Myers Squibb merger
Merger speculation in the pharmaceutical sector ran ahead of reality this week. AstraZeneca (NASDAQ: AZN) shares climbed around 6% on Wednesday after Reuters reported that no discussions are taking place between the company and…
Key takeaways
- AstraZeneca shares rose about 6% on Wednesday after Reuters reported no merger discussions are taking place with Bristol Myers Squibb.
- A senior source told Reuters there is no deal, there never was a deal, and no talks are occurring between the two companies.
- Earlier in the week AstraZeneca shares fell roughly 9% in London, its sharpest single-day drop since 2020, while Bristol Myers Squibb gained around 6% in U.S. pre-market trading when the rumours circulated.
- A combination would have created a group approaching $400 billion in value, with AstraZeneca valued at about $264 billion and Bristol Myers Squibb at around $133 billion.
- AstraZeneca reported Q2 2026 earnings per share of $2.63, beating the consensus forecast of $2.48, and is targeting $80 billion in annual revenue by 2030.
Merger speculation in the pharmaceutical sector ran ahead of reality this week. AstraZeneca (NASDAQ: AZN) shares climbed around 6% on Wednesday after Reuters reported that no discussions are taking place between the company and Bristol Myers Squibb (NYSE: BMY) regarding a combination, deflating a rumour that had briefly wiped billions from AstraZeneca's market value.
The denial and the damage it reversed
A senior source familiar with the matter told Reuters on Wednesday that there is no deal, there never was a deal, and no discussions are taking place between the two companies. The statement arrived after a turbulent stretch: AstraZeneca shares fell roughly 9% in London earlier this week, its sharpest single-day drop since 2020, while Bristol Myers Squibb gained around 6% in U.S. pre-market trading when the rumours first circulated over the weekend. Wednesday's rally recovered part of that decline.
The asymmetry in those moves captured what analysts and shareholders had been saying all along. Jefferies described the proposed combination as "more than a head scratcher," adding that AstraZeneca is one company that does not need financial engineering. Markus Manns, portfolio manager at Union Investment, told Reuters the merger made no strategic or financial sense. Lucy Coutts, investment director at JM Finn, argued the only identifiable benefit for AstraZeneca would have been to accelerate its U.S. presence, while Bristol Myers Squibb shareholders would have been the primary winners.
What a $400 billion deal would have required
Against the backdrop of tightening antitrust scrutiny, the deal faced structural obstacles beyond its contested logic. AstraZeneca is valued at approximately $264 billion; Bristol Myers Squibb at around $133 billion. A combination would have produced a group approaching $400 billion in value, surpassing Bristol Myers Squibb's own $99.6 billion acquisition of Celgene in 2019 as a reference point for mega-deals in the sector.
Antitrust lawyer Andre Barlow of DBM Law Group, cited by FiercePharma, said major asset disposals would likely have been required before regulators considered approval. Both companies compete directly in PD-(L)1 cancer immunotherapy through their respective drugs Opdivo and Imfinzi, and each markets one of the only two commercially available anti-CTLA-4 therapies.
AstraZeneca's independent trajectory
The speculation arrived at an awkward moment for a company delivering strong results on its own terms. AstraZeneca reported second-quarter 2026 earnings per share of $2.63, ahead of the consensus forecast of $2.48, and is targeting annual revenue of $80 billion by 2030. The company completed a direct listing on the New York Stock Exchange in June 2026 and has committed $50 billion to research, development, and manufacturing investment in the United States through 2030.
With regular NYSE trading resuming Wednesday, the sector-wide read-through is whether Bristol Myers Squibb gives back some of the gains built on takeover speculation now that the rationale has publicly collapsed.
Related reading
Source · 來源